LLY Stock Recent News
LLY LATEST HEADLINES
INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago. Lilly will also host an investor event to highlight the company's cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions.
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Eli Lilly NYSE: LLY has transformed from a steady pharmaceutical giant into one of Wall Street's standout growth stories—and it's not just hype. Powered by blockbuster drugs for diabetes and weight loss, a deep pipeline of next-generation treatments, and aggressive investment in future capacity, Lilly is rewriting what long-term success looks like in Big Pharma.
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders.
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.